inhibitor

(redirected from entry inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to entry inhibitor: protease inhibitor, Reverse transcriptase inhibitors, Integrase inhibitor
See: deterrent
References in periodicals archive ?
Peptide-T, an entry inhibitor first discovered in the 1980s but not studied as an anti-HIV drug until the late '90s, is also so well tolerated that codeveloper Pert says one possible use for the drug would be for patients on so-called drug holidays--periods when they stop taking anti-HIV drugs in order to reduce toxic side effects.
On the whole, entry inhibitors appear to be the next new weapon against HIV.
These forward-looking statements include references to potential commercial opportunities provided by the current HIV drug development pipeline, the potential use for the Company's tests in early access programs as well as in commercial use of CCR5 entry inhibitor drugs if approved by the FDA, the expected timing of certain CCR5 clinical trials and the advantages of phenotypic testing over genotypic testing.
Evaluation of HIV resistance to currently approved drugs * Evaluation of resistance and co-receptor usage related to approved and investigational entry inhibitors * Development of novel drug compounds * Exploration of the role of neutralizing antibody responses in refining treatment strategies and developing HIV vaccines * Analysis of replication capacity as a predictor of clinical outcome
The debut of entry inhibitors has been eagerly awaited because of preclinical hints that they may be highly effective and have few side effects.
Three CCR5 entry inhibitors have recently been in large clinical trials: aplaviroc from GlaxoSmithKline, maraviroc from Pfizer, and vicriviroc from Schering Plough.
This could include new class of drugs for entry inhibitors, coreceptor antagonists and fusion inhibitors.
Based on the class of drugs, the market is segmented as follows: - Multi-class combination products - Nucleoside reverse transcriptase inhibitors - Non-nucleoside reverse transcriptase inhibitors - Protease inhibitors - Fusion inhibitors - Entry inhibitors - CCR5 co-receptor antagonist - HIV integrase strand transfer inhibitors The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market.
With a far greater understanding of the HIV cell entry process, we can now envisage HIV entry inhibitors as whole new classes of drugs for the future.
The four new anti-HIV drugs that came out in 2003 are Fuzeon, part of a new class of drugs called entry inhibitors or fusion inhibitors; the protease inhibitors Reyataz and Lexiva; and the reverse transcriptase inhibitor Emtriva.
We also saw data about other new classes of drugs, including many other entry inhibitors, CCR-5 inhibitors, and one drug from a completely new class that may be a viral assembly inhibitor.